JP2010526780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526780A5 JP2010526780A5 JP2010506560A JP2010506560A JP2010526780A5 JP 2010526780 A5 JP2010526780 A5 JP 2010526780A5 JP 2010506560 A JP2010506560 A JP 2010506560A JP 2010506560 A JP2010506560 A JP 2010506560A JP 2010526780 A5 JP2010526780 A5 JP 2010526780A5
- Authority
- JP
- Japan
- Prior art keywords
- viscosity
- retinal
- cps
- sec
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 9
- 208000024891 symptom Diseases 0.000 claims 4
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims 3
- 208000014882 Carotid artery disease Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010070957 Choroidal haemangioma Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000002927 Hamartoma Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010038899 Retinal telangiectasia Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000036038 Subretinal fibrosis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 201000005845 branch retinal artery occlusion Diseases 0.000 claims 1
- 201000005849 central retinal artery occlusion Diseases 0.000 claims 1
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 208000008798 osteoma Diseases 0.000 claims 1
- 229960003407 pegaptanib Drugs 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 201000004849 posterior scleritis Diseases 0.000 claims 1
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000001927 retinal artery Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/742,350 US11078262B2 (en) | 2007-04-30 | 2007-04-30 | High viscosity macromolecular compositions for treating ocular conditions |
| US11/742,350 | 2007-04-30 | ||
| PCT/US2008/061785 WO2008134644A1 (en) | 2007-04-30 | 2008-04-28 | High viscosity macromolecular compositions for treating ocular conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013185340A Division JP6165565B2 (ja) | 2007-04-30 | 2013-09-06 | 眼症状を処置するための高粘度高分子組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526780A JP2010526780A (ja) | 2010-08-05 |
| JP2010526780A5 true JP2010526780A5 (enExample) | 2011-06-16 |
| JP5775301B2 JP5775301B2 (ja) | 2015-09-09 |
Family
ID=39532784
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506560A Expired - Fee Related JP5775301B2 (ja) | 2007-04-30 | 2008-04-28 | 眼症状を処置するための高粘度高分子組成物 |
| JP2013185340A Active JP6165565B2 (ja) | 2007-04-30 | 2013-09-06 | 眼症状を処置するための高粘度高分子組成物 |
| JP2015224266A Expired - Fee Related JP6247272B2 (ja) | 2007-04-30 | 2015-11-16 | 眼症状を処置するための高粘度高分子組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013185340A Active JP6165565B2 (ja) | 2007-04-30 | 2013-09-06 | 眼症状を処置するための高粘度高分子組成物 |
| JP2015224266A Expired - Fee Related JP6247272B2 (ja) | 2007-04-30 | 2015-11-16 | 眼症状を処置するための高粘度高分子組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11078262B2 (enExample) |
| EP (3) | EP2146727B1 (enExample) |
| JP (3) | JP5775301B2 (enExample) |
| KR (2) | KR101800570B1 (enExample) |
| AT (1) | ATE554747T1 (enExample) |
| AU (1) | AU2008245503B2 (enExample) |
| BR (1) | BRPI0810715B8 (enExample) |
| CA (1) | CA2685522C (enExample) |
| ES (3) | ES2386847T3 (enExample) |
| WO (1) | WO2008134644A1 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| KR20060129246A (ko) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | 타입 2 혈관 내피 성장 인자 수용체의 억제제 |
| US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
| EP3252079B8 (en) | 2006-04-07 | 2020-09-09 | Aerpio Therapeutics LLC | Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof |
| SI2944306T1 (sl) | 2006-06-16 | 2021-04-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8586556B2 (en) * | 2006-11-03 | 2013-11-19 | Allergan, Inc. | Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| CA2670471A1 (en) | 2006-11-22 | 2008-06-05 | Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| US8642067B2 (en) * | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| AU2008256819A1 (en) | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Cross-linked collagen and uses thereof |
| US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
| EP2818184B1 (en) | 2007-11-16 | 2018-10-31 | Allergan, Inc. | Compositions and methods for treating Purpura |
| US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
| US9044477B2 (en) | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| CN102007145A (zh) | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| ES2656350T3 (es) | 2008-03-28 | 2018-02-26 | The Regents Of The University Of California | Conjugados polipéptido-polímero y procedimientos de uso de los mismos |
| EP2799448A1 (en) | 2008-05-22 | 2014-11-05 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| US8349806B2 (en) * | 2008-07-10 | 2013-01-08 | Inspire Pharmaceuticals, Inc. | Method of treating blepharitis |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
| AU2009288118B2 (en) | 2008-09-02 | 2014-12-11 | Allergan, Inc. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
| US20100098772A1 (en) * | 2008-10-21 | 2010-04-22 | Allergan, Inc. | Drug delivery systems and methods for treating neovascularization |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| US20100190734A1 (en) * | 2009-01-23 | 2010-07-29 | Romulus Kimbro Brazzell | Method of treating dry eye disease with azithromycin |
| WO2010097800A1 (en) * | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| PE20120622A1 (es) * | 2009-06-17 | 2012-05-26 | Abbott Biotherapeutics Corp | Anticuerpos anti-vegf y sus usos |
| PL2451279T3 (pl) | 2009-07-06 | 2019-09-30 | Aerpio Therapeutics, Inc. | Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| WO2011103599A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The Universith Of California | Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases |
| US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
| DK2550027T4 (da) | 2010-03-22 | 2019-05-13 | Allergan Inc | Tværbundne polysaccharid- og protein-polysaccharid-hydrogeler til blødvævsforøgelse |
| EP2576615B1 (en) | 2010-05-26 | 2016-03-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| WO2012012541A2 (en) | 2010-07-21 | 2012-01-26 | Allergan, Inc. | SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY |
| US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
| US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US20120058187A1 (en) * | 2010-09-03 | 2012-03-08 | Novagali Pharma Sa | Water-in-oil type emulsion for treating a disease of the eye |
| US9107822B2 (en) * | 2010-09-03 | 2015-08-18 | Santen Sas | Water-in oil type emulsion for treating a disease of the eye |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| ES2738208T3 (es) | 2011-06-03 | 2020-01-20 | Allergan Ind Sas | Composiciones de relleno dérmico que incluyen antioxidantes |
| US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| GB201117538D0 (en) * | 2011-10-11 | 2011-11-23 | Royal Veterinary College The | Methods |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint Pharmaceuticals, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| US8912215B2 (en) | 2011-12-13 | 2014-12-16 | Everon Biosciences, Inc. | Rapamycin composition |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| TWI663985B (zh) | 2012-09-27 | 2019-07-01 | 美商歐樂根公司 | 用於持續釋放蛋白質之可生物降解的藥物傳遞系統 |
| US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| EP4101297A1 (en) | 2013-03-15 | 2022-12-14 | Aerpio Pharmaceuticals, Inc. | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| JP6571075B2 (ja) * | 2013-07-08 | 2019-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | アンチセンスオリゴヌクレオチド介在性エクソンスキッピングを、それを必要とする対象の網膜において行うための方法 |
| US9994560B2 (en) | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| CA2978874C (en) * | 2014-03-17 | 2023-08-29 | Encompass Development, Inc. | Ocular formulations comprising a glycosaminoglycan and an anesthetic |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES2761558T3 (es) | 2014-09-30 | 2020-05-20 | Allergan Ind Sas | Composiciones de hidrogel estables que incluyen aditivos |
| WO2016128783A1 (en) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
| PL3256179T3 (pl) | 2015-02-13 | 2020-05-18 | Allergan Industrie, Sas | Implanty do kształtowania, uwydatniania lub korygowania cech twarzy takich jak broda |
| WO2016200688A1 (en) | 2015-06-06 | 2016-12-15 | Cloudbreak Therapeutics, Llc | Compositions and methods for treating pterygium |
| KR102725051B1 (ko) | 2015-09-23 | 2024-11-04 | 제넨테크, 인크. | 항-vegf 항체의 최적화된 변이체들 |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| EP3386520B1 (en) | 2015-12-09 | 2022-07-20 | The Regents of The University of California | Methods of treating an ocular disease or disorder |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| CN108697772B (zh) * | 2015-12-30 | 2022-06-24 | 马歇尔大学科研协会 | 用于治疗视网膜病的组合物和方法 |
| KR102179241B1 (ko) * | 2016-04-22 | 2020-11-16 | 국립암센터 | 병변 표지용 주사제 조성물 |
| KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| CA3097123A1 (en) * | 2018-04-17 | 2019-10-24 | Outlook Therapeutics, Inc. | Buffered formulations of bevacizumab for use of treating diseases |
| CN110755427A (zh) * | 2018-07-28 | 2020-02-07 | 华中科技大学 | 一种治疗视网膜退行性疾病的药物 |
| IT201800007683A1 (it) | 2018-07-31 | 2020-01-31 | Altergon Sa | Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati |
| EP3870204A4 (en) * | 2018-10-24 | 2022-12-21 | Allysta Pharmaceuticals, Inc. | Adiponectin peptidomimetics formulations |
| WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| DE102019112917B4 (de) * | 2019-05-16 | 2021-07-22 | Carl Zeiss Meditec Ag | Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat |
| CN110025768B (zh) * | 2019-06-03 | 2023-03-21 | 上海市第一人民医院 | 一种眼部疾病动物模型的构建方法及其应用 |
| CA3151375A1 (en) * | 2019-08-01 | 2021-02-04 | Kushal Garima | Ophthalmic composition of bevacizumab |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20220387554A1 (en) * | 2021-06-04 | 2022-12-08 | Mark H. Nelson | Treatments for exudative maculopathies |
| US20230310380A1 (en) * | 2022-04-05 | 2023-10-05 | Alan Neil Glazier | Methods, devices, and systems for treating lens protein aggregation diseases |
| CN115040535B (zh) * | 2022-08-15 | 2022-12-16 | 华南理工大学 | 硫酸化透明质酸在制备预防角膜纤维化、角膜瘢痕滴眼液中的应用 |
| CN118903383B (zh) * | 2024-10-09 | 2025-02-25 | 中山大学中山眼科中心 | Vegf-b蛋白、vegf-b蛋白活性肽段在制备预防和/或治疗急性前葡萄膜炎的药物中的应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US166331A (en) | 1875-08-03 | Improvement in motors | ||
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| EP0244178A3 (en) * | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
| CA2088258C (en) | 1990-07-27 | 2004-09-14 | Phillip Dan Cook | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
| DK1695979T3 (da) | 1991-12-24 | 2011-10-10 | Isis Pharmaceuticals Inc | Gappede modificerede oligonukleotider |
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| JP3015464B2 (ja) | 1992-07-23 | 2000-03-06 | アイシス・ファーマシューティカルス・インコーポレーテッド | 新規２’−０−アルキルヌクレオシドおよびホスホロアミダイトの製造法およびその使用 |
| WO1994019023A1 (en) | 1993-02-19 | 1994-09-01 | Isis Pharmaceuticals, Inc. | Cyclobutyl antisense oligonucleotides, methods of making and use thereof |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5527907A (en) | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| JP3208525B2 (ja) | 1995-01-05 | 2001-09-17 | 電気化学工業株式会社 | ヒアルロン酸ナトリウム溶液注射剤および注射用容器 |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7582311B1 (en) | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20050233344A1 (en) | 2001-05-18 | 2005-10-20 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA) |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| CA2526831C (en) | 2001-05-18 | 2012-07-31 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| CA2448320A1 (en) | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
| WO2003000856A2 (en) | 2001-06-21 | 2003-01-03 | Phylos, Inc. | In vitro protein interaction detection systems |
| KR20040058100A (ko) | 2001-11-14 | 2004-07-03 | 알자 코포레이션 | 주입가능한 데포 조성물 및 그의 용도 |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US20050074865A1 (en) | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| WO2004029224A2 (en) | 2002-09-30 | 2004-04-08 | Compound Therapeutics, Inc. | Methods of engineering spatially conserved motifs in polypeptides |
| US7399612B2 (en) * | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| PL1660057T3 (pl) * | 2003-08-27 | 2012-10-31 | Ophthotech Corp | Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej |
| WO2005027906A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| WO2005040379A2 (en) | 2003-10-23 | 2005-05-06 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| WO2005072701A1 (en) | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US7858769B2 (en) | 2004-02-10 | 2010-12-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA) |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| GB2438544A (en) | 2005-02-09 | 2007-11-28 | Cooper Internat Corp | Liquid formulations for treatment of diseases or conditions |
| EP1924292A2 (en) | 2005-09-16 | 2008-05-28 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| MX339797B (es) | 2005-10-18 | 2016-06-10 | Allergan Inc | Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. |
| BRPI0707446A2 (pt) * | 2006-02-02 | 2011-05-03 | Allergan Inc | composições e métodos para o tratamento de doença oftálmica |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8642067B2 (en) * | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US9197705B2 (en) | 2013-04-12 | 2015-11-24 | Samsung Electronics Co., Ltd. | Method and apparatus for supporting driving using wireless communication network and system thereof |
-
2007
- 2007-04-30 US US11/742,350 patent/US11078262B2/en not_active Expired - Fee Related
-
2008
- 2008-04-28 AT AT08747032T patent/ATE554747T1/de active
- 2008-04-28 ES ES08747032T patent/ES2386847T3/es active Active
- 2008-04-28 JP JP2010506560A patent/JP5775301B2/ja not_active Expired - Fee Related
- 2008-04-28 WO PCT/US2008/061785 patent/WO2008134644A1/en not_active Ceased
- 2008-04-28 ES ES12199057.6T patent/ES2541292T3/es active Active
- 2008-04-28 CA CA2685522A patent/CA2685522C/en active Active
- 2008-04-28 KR KR1020167022920A patent/KR101800570B1/ko not_active Expired - Fee Related
- 2008-04-28 ES ES12151895T patent/ES2436203T3/es active Active
- 2008-04-28 EP EP08747032A patent/EP2146727B1/en active Active
- 2008-04-28 EP EP12151895.5A patent/EP2446890B1/en active Active
- 2008-04-28 EP EP12199057.6A patent/EP2606899B1/en not_active Revoked
- 2008-04-28 KR KR1020097024897A patent/KR101652114B1/ko not_active Expired - Fee Related
- 2008-04-28 AU AU2008245503A patent/AU2008245503B2/en not_active Ceased
- 2008-04-28 BR BRPI0810715A patent/BRPI0810715B8/pt active IP Right Grant
-
2013
- 2013-09-06 JP JP2013185340A patent/JP6165565B2/ja active Active
-
2015
- 2015-11-16 JP JP2015224266A patent/JP6247272B2/ja not_active Expired - Fee Related
-
2021
- 2021-08-02 US US17/392,252 patent/US20220106388A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526780A5 (enExample) | ||
| Xu et al. | Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis | |
| JP2007535552A5 (enExample) | ||
| JP6009511B2 (ja) | 萎縮性加齢性黄斑変性の処置方法 | |
| JP6282231B2 (ja) | 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子 | |
| CN101658491B (zh) | 一种治疗角膜碱烧伤的羊膜滴眼液 | |
| US12357564B2 (en) | Methods and compositions for sustained release microparticles for ocular drug delivery | |
| JP2010513542A5 (enExample) | ||
| JP2015508104A5 (enExample) | ||
| RU2014129316A (ru) | Способы ингибирования глазного ангиогенеза | |
| JP7636334B2 (ja) | 治療物質の眼投与のための薬物送達組成物及びその使用法 | |
| JP2009511632A5 (enExample) | ||
| RU2018128980A (ru) | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза | |
| JP2013501579A5 (enExample) | ||
| CN103052367A (zh) | 用于玻璃体内注射的方法、装置及组合物 | |
| Khare et al. | Mucoadhesive polymers for enhancing retention in ocular drug delivery | |
| Yan et al. | Advances in adhesive hydrogels applied for ophthalmology: An overview focused on the treatment | |
| JP2013523748A5 (enExample) | ||
| JP2018523673A5 (enExample) | ||
| JPWO2022056392A5 (enExample) | ||
| JP2013513606A5 (enExample) | ||
| CA3129429A1 (en) | Antioxidant-releasing vitreous substitutes and uses thereof | |
| JP2013501794A (ja) | 目の疾患を治療するためのイソチオゾール | |
| JPWO2020163871A5 (enExample) | ||
| Bleau et al. | Managing intraocular pressure: innovation in glaucoma management |